News & Updates

Certain rheuma therapies tied to poorer COVID-19 outcomes, impaired vaccine response

19 Jun 2021 by

Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.

Certain rheuma therapies tied to poorer COVID-19 outcomes, impaired vaccine response

19 Jun 2021

COVID-19 vaccine safe in people with rheumatic diseases

17 Jun 2021 by

Data from the EULAR COVID-19 Vaccination (COVAX) Registry showed that available COVID-19 vaccines were safe and well tolerated in patients with rheumatic and musculoskeletal diseases (RMDs).

COVID-19 vaccine safe in people with rheumatic diseases

17 Jun 2021

Atorvastatin: Is there evidence of benefit in COVID-19?

17 Jun 2021 by

Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.

Atorvastatin: Is there evidence of benefit in COVID-19?

17 Jun 2021

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

17 Jun 2021 by

The human monoclonal antibody mavrilimumab reduced the rates of mechanical ventilation and death in nonmechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation, according to a phase II/III study presented at EULAR 2021.

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

17 Jun 2021

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

16 Jun 2021 by

Patients with psoriasis may be at an increased risk of contracting COVID-19, according to a study presented at AAD VMX 2021.

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

16 Jun 2021

COPD tied to excess death risk, even in younger adults

15 Jun 2021 by

Younger adults with chronic obstructive pulmonary disease (COPD) have excess risk of morbidity and mortality, contrary to common belief that the disease is mild at younger age, according to a longitudinal, population-base cohort study presented at the ATS 2021 Meeting.

COPD tied to excess death risk, even in younger adults

15 Jun 2021

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

15 Jun 2021

The fixed-dosing omadacycline strategy demonstrates consistent safety and efficacy in patients with community-acquired bacterial pneumonia (CABP), regardless of body mass index (BMI), according to a phase III trial.

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

15 Jun 2021

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021 by

Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

13 Jun 2021 by

In hospitalized COVID-19 patients with elevated D-dimer levels who were under stable condition, initial in-hospital anticoagulation using a therapeutic dose of rivaroxaban 20 mg did not improve clinical outcomes compared with standard prophylactic anticoagulation, according to the ACTION* trial presented at ACC.21 Meeting.

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

13 Jun 2021

Abdominal muscle thickening tied to weaning outcomes in mechanically ventilated patients

13 Jun 2021

Mechanically ventilated patients use their abdominal muscles during spontaneous breathing and when coughing, and a recent study shows that those with reduced abdominal muscle thickness on ultrasound are likely to be kept on mechanical ventilation.

Abdominal muscle thickening tied to weaning outcomes in mechanically ventilated patients

13 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Certain rheuma therapies tied to poorer COVID-19 outcomes, impaired vaccine response

Certain rheuma therapies tied to poorer COVID-19 outcomes, impaired vaccine response

COVID-19 vaccine safe in people with rheumatic diseases

COVID-19 vaccine safe in people with rheumatic diseases

Atorvastatin: Is there evidence of benefit in COVID-19?

Atorvastatin: Is there evidence of benefit in COVID-19?

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

COPD tied to excess death risk, even in younger adults

COPD tied to excess death risk, even in younger adults

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

PAP-treated sleep apnoea tied to reduced COVID-19 risk

PAP-treated sleep apnoea tied to reduced COVID-19 risk

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

Abdominal muscle thickening tied to weaning outcomes in mechanically ventilated patients

Abdominal muscle thickening tied to weaning outcomes in mechanically ventilated patients